First Time Loading...

ASKA Pharmaceutical Holdings Co Ltd
TSE:4886

Watchlist Manager
ASKA Pharmaceutical Holdings Co Ltd Logo
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Watchlist
Price: 2 267 JPY -1.18% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
ASKA Pharmaceutical Holdings Co Ltd

Wall Street analysts forecast ASKA Pharmaceutical Holdings Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASKA Pharmaceutical Holdings Co Ltd is 2 499 JPY with a low forecast of 2 424 JPY and a high forecast of 2 625 JPY.

Lowest Forecast
Wall Street Target
2 424 JPY
7% Upside
Average Forecast
Wall Street Target
2 499 JPY
10% Upside
Highest Forecast
Wall Street Target
2 625 JPY
16% Upside
Lowest
Price Target
2 424 JPY
7% Upside
Average
Price Target
2 499 JPY
10% Upside
Highest
Price Target
2 625 JPY
16% Upside
ASKA Pharmaceutical Holdings Co Ltd Competitors:
Price Targets
G
002424
Guizhou Bailing Group Pharmaceutical Co Ltd
241% Upside
SANOFI
Sanofi India Ltd
9% Upside
600572
Zhejiang CONBA Pharmaceutical Co Ltd
11% Upside
SOLARA
Solara Active Pharma Sciences Ltd
26% Downside
G
002424
Guizhou Bailing Group Pharmaceutical Co Ltd
241% Upside
SANOFI
Sanofi India Ltd
9% Upside
600572
Zhejiang CONBA Pharmaceutical Co Ltd
11% Upside
SOLARA
Solara Active Pharma Sciences Ltd
26% Downside
SUPRIYA
Supriya Lifescience Ltd
3% Upside
A
000739
Apeloa Pharmaceutical Co Ltd
50% Upside
H
243070
Huons Co Ltd
70% Upside
001630
Chongkundang Holdings Corp
15% Upside

Revenue
Forecast

Revenue Estimate
ASKA Pharmaceutical Holdings Co Ltd

For the last 6 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 3%.

4%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ASKA Pharmaceutical Holdings Co Ltd

Operating Income forecast
is not available for
ASKA Pharmaceutical Holdings Co Ltd

Net Income
Forecast

Net Income Estimate
ASKA Pharmaceutical Holdings Co Ltd

For the last 6 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's net income is 6%. The projected CAGR for the next 3 years is 6%.

6%
Past Growth
6%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASKA Pharmaceutical Holdings Co Ltd's stock price target?
Price Target
2 499 JPY

According to Wall Street analysts, the average 1-year price target for ASKA Pharmaceutical Holdings Co Ltd is 2 499 JPY with a low forecast of 2 424 JPY and a high forecast of 2 625 JPY.

What is ASKA Pharmaceutical Holdings Co Ltd's Revenue forecast?
Projected CAGR
3%

For the last 6 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 3%.

What is ASKA Pharmaceutical Holdings Co Ltd's Net Income forecast?
Projected CAGR
6%

For the last 6 years the compound annual growth rate for ASKA Pharmaceutical Holdings Co Ltd's net income is 6%. The projected CAGR for the next 3 years is 6%.

ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.